Related Experiment Video
Updated: May 24, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
New and future immunomodulatory therapy in type 1 diabetes
James E Tooley1, Frank Waldron-Lynch, Kevan C Herold
1Department of Immunobiology, Yale University, New Haven, CT 06511, USA.
Trends in Molecular Medicine
|February 21, 2012
Summary
Type 1 diabetes, an autoimmune disease, involves pancreatic beta cell destruction, necessitating lifelong insulin. Recent research focuses on new immunomodulatory treatments to combat this growing global health challenge.
Area of Science:
- Immunology
- Endocrinology
- Diabetology
Background:
- Type 1 diabetes is a prevalent autoimmune condition characterized by the destruction of pancreatic beta cells.
- The incidence of type 1 diabetes is rising globally, particularly in young children.
- Chronic hyperglycemia resulting from insulin deficiency leads to severe secondary end-organ complications.
Purpose of the Study:
- To review recent advancements in the immunomodulatory treatment of type 1 diabetes.
- To highlight progress in understanding the pathogenesis of type 1 diabetes.
- To discuss the potential of novel therapeutic strategies.
Main Methods:
- Literature review of recent studies on type 1 diabetes pathogenesis.
- Analysis of emerging immunomodulatory treatment approaches.
- Synthesis of current research on therapeutic interventions.
Main Results:
- Significant progress has been made in understanding the autoimmune mechanisms underlying type 1 diabetes.
- Several novel immunomodulatory treatments are under investigation.
- Despite promising developments, no new treatments have yet received regulatory approval.
Conclusions:
- Continued research into type 1 diabetes pathogenesis is crucial for developing effective therapies.
- Immunomodulatory treatments represent a promising avenue for managing type 1 diabetes.
- Further clinical trials are needed to evaluate the safety and efficacy of new treatments.
More Related Videos
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...